Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

CJMB

C

Callan JMB Inc. (CJMB)

NCM – Real vaqt narxi. Valyuta: USD

1.28

-0.52 (-28.89%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.29

+0.01 (0.78%)

Bozordan keyin: Mar 27, 2026, 7:57 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement

Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement

Independent oversight reinforces manufacturing, supply chain integrity, and federal readiness for a platform designed to scale across multiple indications

Callan JMB Inc. (CJMB) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Transcript

Callan JMB Inc. (CJMB) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Transcript

Callan JMB Inc. (CJMB) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Transcript

Callan JMB Inc. (NASDAQ:CJMB) Announces Major Strategic Pivot to Cold-Chain Infrastructure for the $100 Billion GLP-1 Pharmaceutical Market; Initiates Retrofitting of Texas cGMP Facility

Callan JMB Inc. (NASDAQ:CJMB) Announces Major Strategic Pivot to Cold-Chain Infrastructure for the $100 Billion GLP-1 Pharmaceutical Market; Initiates Retrofitting of Texas cGMP Facility

GALVESTON, TX / ACCESS Newswire / January 12, 2026 / Callan JMB Inc. (NASDAQ:CJMB), a premier provider of vertically integrated temperature-controlled logistics and specialized life sciences fulfillment, today announced a comprehensive strategic realignment to address the critical infrastructure gap in the global distribution of GLP-1 (glucagon-like peptide-1) medications. As the pharmaceutical industry faces a logistics bottleneck due to the meteoric rise of weight-management and diabetes treatments such as Ozempic®, Wegovy®, and Mounjaro®, Callan JMB is positioning its proprietary cold-chain technology to become the primary "last-mile" fulfillment partner for large-scale telehealth and pharmaceutical distributors.

Callan JMB Expands Logistics Platform Into Food Sampling Sector, Advancing Multi-Variant Growth Strategy

Callan JMB Expands Logistics Platform Into Food Sampling Sector, Advancing Multi-Variant Growth Strategy

Move leverages the Company's expertise in regulated materials to capture opportunities in sustainable , high-growth consumer markets

Callan JMB Extends Long-Term Contract with City of Chicago and Receives Increase in Funding

Callan JMB Extends Long-Term Contract with City of Chicago and Receives Increase in Funding

Contract Increase Extends Seven-Year Partnership through June 2026 with Price Increase of $1.5 Million to Total Value of $9.1 Million

Videolar

No Data

There is no data to display

Press-relizlar

Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement

Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement

Independent oversight reinforces manufacturing, supply chain integrity, and federal readiness for a platform designed to scale across multiple indications

Callan JMB Inc. (NASDAQ:CJMB) Announces Major Strategic Pivot to Cold-Chain Infrastructure for the $100 Billion GLP-1 Pharmaceutical Market; Initiates Retrofitting of Texas cGMP Facility

Callan JMB Inc. (NASDAQ:CJMB) Announces Major Strategic Pivot to Cold-Chain Infrastructure for the $100 Billion GLP-1 Pharmaceutical Market; Initiates Retrofitting of Texas cGMP Facility

GALVESTON, TX / ACCESS Newswire / January 12, 2026 / Callan JMB Inc. (NASDAQ:CJMB), a premier provider of vertically integrated temperature-controlled logistics and specialized life sciences fulfillment, today announced a comprehensive strategic realignment to address the critical infrastructure gap in the global distribution of GLP-1 (glucagon-like peptide-1) medications. As the pharmaceutical industry faces a logistics bottleneck due to the meteoric rise of weight-management and diabetes treatments such as Ozempic®, Wegovy®, and Mounjaro®, Callan JMB is positioning its proprietary cold-chain technology to become the primary "last-mile" fulfillment partner for large-scale telehealth and pharmaceutical distributors.

Callan JMB Expands Logistics Platform Into Food Sampling Sector, Advancing Multi-Variant Growth Strategy

Callan JMB Expands Logistics Platform Into Food Sampling Sector, Advancing Multi-Variant Growth Strategy

Move leverages the Company's expertise in regulated materials to capture opportunities in sustainable , high-growth consumer markets

Callan JMB Extends Long-Term Contract with City of Chicago and Receives Increase in Funding

Callan JMB Extends Long-Term Contract with City of Chicago and Receives Increase in Funding

Contract Increase Extends Seven-Year Partnership through June 2026 with Price Increase of $1.5 Million to Total Value of $9.1 Million